Galapagos (GLPG) announces that the EMA's Committee for Medicinal Products for Human Use ((CHMP)) has issued a positive opinion for Jyseleca (filgotinib), a once-daily, oral,...
After 22 years at the helm of Galapagos NV (NASDAQ: GLPG), chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership.He will stay in...
Here's a roundup of top developments in ...Full story available on Benzinga.com
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 5,866.00 | 5,952.00 | 5,850.00 | -84.0 | -1.41% | 549.46K | London | |||
| 957.80 | 971.00 | 953.00 | -17.80 | -1.82% | 1.27M | London | |||
| 2,469.00 | 2,489.00 | 2,461.00 | -18.0 | -0.72% | 267.22K | London | |||
| 320.20 | 321.20 | 315.30 | +2.45 | +0.77% | 36.72M | London | |||
| 539.00 | 540.00 | 530.00 | +10.00 | +1.89% | 16.45K | London | |||
| 1.00 | 1.00 | 0.00 | 0.000 | 0.00% | 0.00 | London | |||
| 145.50 | 145.50 | 145.50 | 0.00 | 0.00% | 47.27K | London | |||
| 1,101.00 | 1,117.50 | 1,090.50 | -28.00 | -2.48% | 1.16M | London | |||
| 16.30 | 16.70 | 16.30 | +0.050 | +0.30% | 8.18M | London | |||
| 1,388.00 | 1,414.00 | 1,386.00 | -26.00 | -1.84% | 6.97M | London | |||
| 295.50 | 296.50 | 293.50 | -0.40 | -0.14% | 3.96M | London | |||
| 3,079.00 | 3,122.00 | 3,068.00 | -41.0 | -1.31% | 148.35K | London | |||
| 375.45 | 377.00 | 372.45 | -1.40 | -0.37% | 12.47M | London | |||
| 183.74 | 185.40 | 181.70 | -0.22 | -0.12% | 29.64M | London | |||
| 825.00 | 833.00 | 819.00 | -8.00 | -0.96% | 644.77K | London |
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.